Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they ...

Pfizer discontinues obesity pill danuglipron after potential drug-induced liver injury in trial patient; company has GIP ...

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad ...

Scientists develop STITCHR, a retrotransposon-based gene editing tool, by Omar Abudayyeh (Mass General Brigham) and Jonathan ...

Alzheon's valiltramiprosate (ALZ-801) fails Phase 3 trial in Alzheimer's patients with APOE4 gene copies, showing no ...

Under the 11-page 'roadmap' outlined Thursday, the goal is for animal testing to become 'the exception rather than the norm' ...

After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Cancer Immunotherapy as president of research.

VC execs write to Sen. Cassidy about FDA staffing concerns, citing delays & uncertainties due to loss of experienced staff & ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Trump signals imminent pharma tariffs, with experts including Mollie Sitkowski of Faegre Drinker suggesting 25% levy possible ...

A biotech incubated by RA Capital has secured a $57.5 million Series B to begin a mid-stage trial for its cardio drug this ...

Cartesian Therapeutics reports sustained benefits of Descartes-08 CAR-T therapy in generalized myasthenia gravis patients, ...